JLE

Hépato-Gastro & Oncologie Digestive

MENU

Cicatrisation histologique au cours des MICI : jusqu’où optimiser ? Volume 26, supplément 3, Novembre 2019

  • [1] Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in Inflammatory Bowel Diseases (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015 ; 110 : 1324-1338.
  • [2] Sipponen T., Kärkkäinen P., Savilahti E. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's Disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-1229.
  • [3] Colombel J.F., Sandborn W.J., Reinisch W. Infliximab, azathioprine, or combination therapy for Crohn's Disease. N Engl J Med. 2010;362:1383-1395.
  • [4] Rutgeerts P., Gasink C., Chan D. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn's Disease. Gastroenterology. 2018;155:1045-1058.
  • [5] Noman M., Ferrante M., Bisschops R. Vedolizumab induces long-term mucosal healing in patients with Crohn's Disease and Ulcerative Colitis. J Crohns Colitis. 2017;11:1085-1089.
  • [6] Matsumoto T., Motoya S., Watanabe K. Adalimumab monotherapy and a combination with azathioprine for Crohn's Disease: A prospective, randomized trial. J Crohns Colitis. 2016;10:1259-1266.
  • [7] Ferrante M, Colombel JF, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn's Disease Based on a post hoc analysis of data from SONIC. Gastroenterology 2013 ; 145 : 978-986.
  • [8] Bryant R.V., Winer S., Travis S.P.L. Systematic review: Histological remission in inflammatory boewl disease. Is « complete » remission the new treatment paradigm ? An IOIBD initiative. J Crohns Colitis. 2014;8:1582-1597.
  • [9] Molander P., Sipponen T., Kemppainen H. Achievement of deep remission during scheduled maintenance therapy with TNF (-blocking agents in IBD. J Crohns Colitis. 2013;7:730-735.
  • [10] Brennan G.T., Melton S.D., Spechler S.J., Feagins L.A. Clinical implications of histologic abnormalities in ileocolonic biopsies of patients with Crohn's Disease in remission. J Clin Gastroenterol. 2017;51:43-48.
  • [11] Baars J.E., Nuij V.J., Oldenburg B., Kuipers E.J., van der Woude C.J. Majority of patients with Inflammatory Bowel Disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18:1634-1640.
  • [12] Novak G., Parker C.E., Pai R.K. Histologic scoring indices for evaluation of disease activity in Crohn's Disease. Cochrane Database Syst Rev. 2017;7:CD012351.
  • [13] Novak G., Stevens T., Van Viegen T. Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's Disease. Aliment Pharmacol Ther. 2019;49:1401-1409.
  • [14] Mantzaris G.J., Christidou A., Sfakianakis M. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's Disease. Inflamm Bowel Dis. 2009;15:375-382.
  • [15] Juncadella A., Papamichael K., Vaughn B.P. Maintenance adalimumab concentrations are associated with biochemical, endoscopic, and histologic remission in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63:3067-3073.
  • [16] Papamichael K., Rakowsky S., Rivera C. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn's Disease. Inflamm Bowel Dis. 2018;24:2266-2271.
  • [17] Li K. Efficacy of Ustekinumab for Induction and Maintenance of Histological Healing in Patient's with Crohn's Disease. Gastroenterology. 2017;152:S595. 5
  • [18] Löwenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn's Disease. Gastroenterology 2019 ; 157 (4) : 997-1006.
  • [19] Narang V., Kaur R., Garg B. Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis. Intest Res. 2018;16:55-61. 1
  • [20] Ponte A., Pinho R., Fernandes S. Impact of histological and endoscopic remissions on clinical recurrence and recurrence-free time in Ulcerative Colitis. Inflamm Bowel Dis. 2017;23:2238-2244.
  • [21] Frieri G., Galletti B., Di Ruscio M. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine. Therap Adv Gastroenterol. 2017;10:749-759.
  • [22] Bryant R.V., Burger D.C., Delo J. Beyond endoscopic mucosal healing in UC: Histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-414.
  • [23] Christensen B., Hanauer S.B., Erlich J. Histologic normalization occurs in Ulcerative Colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017;15:1557-1564.
  • [24] Peyrin Biroulet L., Bressenot A., Kampman W. Histologic remission: The ultimate therapeutic goal in ulcerative colitis ? Clin Gastroenterol Hepatol. 2014;12:929-934.
  • [25] Isaacs K.L. How rapidly should remission be achieved. Dig Dis. 2010;28:548-555.
  • [26] Riley S.A., Mani V., Goodman M.J. Microscopic activity in ulcerative colitis: What does it mean ? Gut. 1991;32:174-178.
  • [27] Travis S.P.L., Higgins P.D.R., Orchard T. Review article: Defining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;34:113-124.
  • [28] Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study. Gastroenterology 2007 ; 133 : 1099-1105.
  • [29] Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000 ; 47 : 404-409.
  • [30] Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. Gut 2017 ; 66 ; 43-9.
  • [31] Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gastroenterology 2017 ; 66 : 50-58.
  • [32] Magro F, Lopes J, Borralho P, et al. Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut 2019 ; 68 : 594-603.
  • [33] Geboes K., Rutgeerts P., Wilkinson K. Infliximab results in reduction of inflammation and inflammatorymarkers in the mucosa of ulcerative colitis patients. Am J Gastroenterol. 2005;100:S287.
  • [34] Wiernicka A., Szymanska S., Cielecka-Kuszyk J. Histological healing after infliximab induction therapy in children with ulcerative colitis. World J Gastroenterol. 2015;21:10654-10661.
  • [35] Fernández-Blanco J.I., Fernández-Díaz G., Cara C. Adalimumab for induction of histological remission in moderately to severely active Ulcerative Colitis. Dig Dis Sci. 2018;63:731-737.
  • [36] Arijs I., De Hertogh G., Lemmens B. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67:43-52.
  • [37] Li K, FriedmanJR, Marano C, et al. Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in Ulcerative Colitis. DOP 071 ; ECCO 2019 Copenhague.
  • [38] Kruis W., Kiudelis G., Racz I. Once daily versus three times daily mesalazine granules in active ulcerative colitis : A doule-blind, double-dummy, radomised, non-inferiority trial. Gut. 2009;58:233-240.